However, the assessment of IL-10 concentration in the blood plasma of patients did not allow for distinguishing patients with early MASLD from those with advanced MASLD inflammation; the only difference was noticed between the entire study group and the control group. Here, IL10 is linked to metabolic dysfunction-associated steatotic liver disease.